Home › Parkinson's Disease › NCT05656586
Udall Project 2 Aim 2A&C
Mechanisms and Effects of Pallidal Deep Brain Stimulation on Levodopa Resistant Motor Signs in Parkinson's Disease; Udall Project 2 Aim 2A&C
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Receiving DBS therapy in GP for treatment of PD * Implanted with Medtronic Percept DBS system * At least 3 months since initial activation of the neurostimulator * For the "At Home" experiment only: participants with DBS settings that are sensing compatible. Exclusion Criteria: * history of musculoskeletal disorders that significantly affects the ability to perform the motor tasks in the specific experiment in question * history of dementia or cognitive impairment * other significant neurological disorder as determined by the PI * post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment * lack of capacity to consent (as identified by MaCAT-CR)
About the study
This protocol will leverage the novel (on-label, FDA-approved) local field potential measuring capability of the Medtronic Percept™ PC or RC DBS system to study the effects of globus pallidus internus, globus pallidus externus (GPi, GPe), and subthalamic nucleus (STN) DBS on: the wash-out and wash-in dynamics of motor behavior and local field potentials (LFPs) and correlations between fluctuations in gait and LFPs during activities of daily living (recorded over a minimum of 4 weeks). These experiments will elucidate the relationships between LFPs oscillations, lower limb function, postural control and gait performance.
What is being tested
- observational-- no intervention (other)
Sponsor: University of Minnesota · Participants: 36 · Started: Jan 1, 2023
Contact the study team
- Colum Mackinnon, PhD · Phone: 612-625-8938
Official record on ClinicalTrials.gov — NCT05656586
Locations in the U.S.
| Minnesota | University of Minnesota, Minneapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.